Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers

BRCA1-associated tumors are characterized by an elevated genomic instability and peculiar expression profiles. Nevertheless, tailored treatments for BRCA1 mutation carriers have only been partially investigated up to now. The implementation of therapeutic strategies specific for these patients has been in part hindered by the paucity of proper preneoplastic and neoplastic BRCA1-deficient tumor cell models. In this study, we took advantage of the RNA interference technology to generate a series of partially transformed (HBL100) and tumorigenic (MCF7 and T47D) breast cancer cell lines in which BRCA1 expression was silenced at different levels. These cell models were probed by clonogenic assay for their response to several DNA-damaging agents commonly used in cancer therapy (mitomycin C, cisplatin, doxorubicin, and etoposide). Our models confirmed the peculiar sensitivity to interstrand cross-link inducers associated with BRCA1 deficiency. Intriguingly, the increased sensitivity to these compounds displayed by BRCA1-defective cells was not correlated with the extent of apoptotic cell death but rather associated to an increased fraction of growth-arrested, enlarged, multinucleated β-galactosidase–positive senescent cells. Overall, our results support a role for BRCA1 in the regulation of interstrand cross-link–induced premature senescence and suggest a reconsideration of the therapeutic power of mitomycin/platinum-based treatments in BRCA1 carriers. Moreover, our data further prompt the setup of strategies for the imaging of the senescence response in vivo. [Mol Cancer Ther 2009;8(4):844–54]

[1]  A. Ashworth,et al.  Targeted therapy for cancer using PARP inhibitors. , 2008, Current opinion in pharmacology.

[2]  Ying Yan,et al.  Gamma-irradiation-induced DNA damage checkpoint activation involves feedback regulation between extracellular signal-regulated kinase 1/2 and BRCA1. , 2008, Cancer research.

[3]  Junjie Chen,et al.  New players in the BRCA1-mediated DNA damage responsive pathway. , 2008, Molecules and cells.

[4]  P. Johnston,et al.  BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy , 2007, Clinical Cancer Research.

[5]  S. Linder,et al.  Mechanisms of action of DNA-damaging anticancer drugs in treatment of carcinomas: is acute apoptosis an "off-target" effect? , 2007, Mini reviews in medicinal chemistry.

[6]  Haesun Choi,et al.  We should desist using RECIST, at least in GIST. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Gelman,et al.  Further Evidence for BRCA1 Communication with the Inactive X Chromosome , 2007, Cell.

[8]  K. Kiura,et al.  Gefitinib induces premature senescence in non-small cell lung cancer cells with or without EGFR gene mutation. , 2007, Oncology reports.

[9]  A. Howell,et al.  Late Toxicity Is Not Increased in BRCA1/BRCA2 Mutation Carriers Undergoing Breast Radiotherapy in the United Kingdom , 2006, Clinical Cancer Research.

[10]  A. Howell,et al.  Acute Chemotherapy–Related Toxicity Is Not Increased in BRCA1 and BRCA2 Mutation Carriers Treated for Breast Cancer in the United Kingdom , 2006, Clinical Cancer Research.

[11]  M. Hande,et al.  A role for Brca1 in chromosome end maintenance. , 2006, Human molecular genetics.

[12]  Jasmyn A. Dunn,et al.  Disruption of BRCA1 function results in telomere lengthening and increased anaphase bridge formation in immortalized cell lines , 2006, Genes, chromosomes & cancer.

[13]  S. Powell,et al.  BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. , 2005, Cancer research.

[14]  Rong Li,et al.  BRCA1: A locus‐specific “liaison” in gene expression and genetic integrity , 2005, Journal of cellular biochemistry.

[15]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[16]  L. Attardi,et al.  The role of apoptosis in cancer development and treatment response , 2005, Nature Reviews Cancer.

[17]  Yoshio Miki,et al.  Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage , 2004, Cancer science.

[18]  L. Chodosh,et al.  Brca1-Deficient Murine Mammary Epithelial Cells have Increased Sensitivity to CDDP and MMS , 2004, Cell cycle.

[19]  William D. Foulkes,et al.  Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer , 2004 .

[20]  L. Bégin,et al.  Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.

[21]  R. Eeles,et al.  Primary fibroblasts from BRCA1 heterozygotes display an abnormal G1/S cell cycle checkpoint following UVA irradiation but show normal levels of micronuclei following oxidative stress or mitomycin C treatment. , 2004, International journal of radiation oncology, biology, physics.

[22]  P. Johnston,et al.  BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. , 2003, Cancer research.

[23]  P. Jeggo,et al.  A subset of ATM‐ and ATR‐dependent phosphorylation events requires the BRCA1 protein , 2003, The EMBO journal.

[24]  A. Fedier,et al.  The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. , 2003, International journal of oncology.

[25]  C. Boland,et al.  BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells , 2003, British Journal of Cancer.

[26]  Y. Miyoshi,et al.  Increased Expression of BRCA1 mRNA Predicts Favorable Response to Anthracycline-Containing Chemotherapy in Breast Cancers , 2003, Breast Cancer Research and Treatment.

[27]  L. Bégin,et al.  Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma , 2003, Cancer.

[28]  P. Chappuis,et al.  A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer , 2002, Journal of medical genetics.

[29]  Soyoung Lee,et al.  A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy , 2002, Cell.

[30]  S. Joel,et al.  DNA damage is able to induce senescence in tumor cells in vitro and in vivo. , 2002, Cancer research.

[31]  D. Papadopoulo,et al.  A single mutated BRCA1 allele leads to impaired fidelity of double strand break end-joining , 2002, Oncogene.

[32]  Ashok R Venkitaraman,et al.  Cancer Susceptibility and the Functions of BRCA1 and BRCA2 , 2002, Cell.

[33]  R. Kanaar,et al.  Repair of DNA interstrand cross-links. , 2001, Mutation research.

[34]  M. Jasin,et al.  Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. , 2001, Cancer research.

[35]  T. Aas,et al.  Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. , 2001, Cancer research.

[36]  Alexander Kinev,et al.  BRCA1 Is Associated with a Human SWI/SNF-Related Complex Linking Chromatin Remodeling to Breast Cancer , 2000, Cell.

[37]  J. Boyd,et al.  Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. , 2000, JAMA.

[38]  S. Elledge,et al.  BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. , 2000, Genes & development.

[39]  Å. Borg,et al.  Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. , 2000, The American journal of pathology.

[40]  E. Kandel,et al.  A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. , 1999, Cancer research.

[41]  R. Souhami,et al.  Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  S. Linder,et al.  Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA , 2007, International journal of cancer.

[43]  W. Foulkes.  BRCA1 and BRCA2: Chemosensitivity, Treatment Outcomes and Prognosis , 2005, Familial Cancer.